VEGF165, Bcl-2, p53, COX-2 and HER-family expression in patients with stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) and correlation with clinical outcome.

被引：0
|
作者：
Timotheadou, E
Murray, S
Linardou, H
Vrettou, AV
Skrickova, J
Kosmidis, P
Skarlos, DV
Pectasides, D
Fountzilas, G
机构：
[1] Papageorgiou Hosp, Dept Med Oncol, Thessaloniki, Greece
[2] Mol Biol & Genet Metropolitan Hosp, Athens, Greece
[3] Metropolitan Hosp, Dept Oncol, Athens, Greece
[4] Univ Hosp Brno, Brno, Czech Republic
[5] HYGEIA Hosp, Oncol Pathol Clin 2, Athens, Greece
[6] Errikos Dunant Hosp, B Oncol Dept, Athens, Greece
[7] Univ Athens, Attikon Hosp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：681S / 681S
页数：1
相关论文
共 50 条
  • [41] Prognostic significance of immunohistochemical expression of bcl-2, p53 and ki67 in early operable non-small cell lung cancer
    Tsobanidou, Xristina
    Boukovinas, Ioannis
    Papageorgiou, Athanasios
    Anestakis, Dimitrios
    Barbetakis, Nikolaos
    Papakotoulas, Pavlos
    Xenidis, Nikolaos
    Ligdas, Athanasios
    Toliou, Theofano
    ANNALS OF ONCOLOGY, 2006, 17 : 253 - 253
  • [42] Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer
    Ludovini, V
    Gregorc, V
    Pistola, L
    Mihaylova, Z
    Floriani, I
    Darwish, S
    Stracci, F
    Tofanetti, FR
    Ferraldeschi, M
    Di Carlo, L
    Ragusa, M
    Daddi, G
    Tonato, M
    LUNG CANCER, 2004, 46 (01) : 77 - 85
  • [43] Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101)
    Yamaguchi, Masafumi
    Tada, Hirohito
    Mitsudomi, Tetsuya
    Seto, Takashi
    Yokoi, Kohei
    Katakami, Nobuyuki
    Nakagawa, Kazuhiko
    Oda, Makoto
    Ohta, Mitsunori
    Sawa, Toshiyuki
    Yamashita, Motohiro
    Iked, Norihiko
    Saka, Hideo
    Higashiyama, Masahiko
    Nomori, Hiroaki
    Semba, Hiroshi
    Negoro, Shunichi
    Chiba, Yasutaka
    Shimokawa, Mototsugu
    Fukuoka, Masahiro
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2216 - 2223
  • [44] A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.
    Jie, H.
    Xiangru, Z.
    Han, B.
    Liu, Y.
    Wang, Q.
    Xu, S.
    Sheng, Y.
    Li, Q.
    Wu, S.
    Chen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Valsamo K Anagnostou
    Frank J Lowery
    Vassiliki Zolota
    Vassiliki Tzelepi
    Arun Gopinath
    Camil Liceaga
    Nikolaos Panagopoulos
    Konstantina Frangia
    Lynn Tanoue
    Daniel Boffa
    Scott Gettinger
    Frank Detterbeck
    Robert J Homer
    Dimitrios Dougenis
    David L Rimm
    Konstantinos N Syrigos
    BMC Cancer, 10
  • [46] Randomized clinical trial of adjuvant chemotherapy with docetaxel and carboplatin for completely resected stage IB to IIIA non-small cell lung cancer (NSCLC): Preliminary result of Chinese society of lung cancer (CSLC) protocol 0201
    Yang, X
    Wu, Y
    Chen, G
    Xu, L
    Gu, L
    Tang, P
    Zhu, Y
    Xiao, P
    Tang, J
    Xie, L
    LUNG CANCER, 2005, 49 : S97 - S97
  • [47] High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Anagnostou, Valsamo K.
    Lowery, Frank J.
    Zolota, Vassiliki
    Tzelepi, Vassiliki
    Gopinath, Arun
    Liceaga, Camil
    Panagopoulos, Nikolaos
    Frangia, Konstantina
    Tanoue, Lynn
    Boffa, Daniel
    Gettinger, Scott
    Detterbeck, Frank
    Homer, Robert J.
    Dougenis, Dimitrios
    Rimm, David L.
    Syrigos, Konstantinos N.
    BMC CANCER, 2010, 10
  • [48] Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
    Feng, Wen
    Li, Yuan
    Shen, Lei
    Cai, Xu-Wei
    Zhu, Zheng-Fei
    Chang, Jian-Hua
    Xiang, Jia-Qing
    Zhang, Ya-Wei
    Chen, Hai-Quan
    Fu, Xiao-Long
    ONCOTARGET, 2016, 7 (06) : 7227 - 7240
  • [49] Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients with Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
    Feng, Wen
    Li, Yuan
    Fu, Xiaolong
    Shen, Lei
    Cai, Xuwei
    Zhu, Zhengfei
    Chang, Jianhua
    Xiang, Jiaqing
    Zhang, Yawei
    Chen, Haiquan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S244 - S244
  • [50] P53 Her2/neu as prognostic factors in advanced non-small cell lung cancer (NSCLC) treated with paclitaxel
    Yumuk, R
    Turhal, N
    Ahiskali, R
    Gumus, M
    Hatabay, N
    Turken, O
    Ozkan, A
    Salepci, T
    Aliustaoglu, M
    LUNG CANCER, 2005, 49 : S152 - S152
12345